Eli Lilly’s (NYSE:LLY) experimental obesity therapy eloralintide has caused up to 11% weight loss over 12 weeks in an ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Eli Lilly's share price is down about 6.4% over the past year. The pharmaceutical giant's weight-loss drugs continue to drive ...

Jewelry shops are seeing an increase in business due to the popularity of weight loss drugs. Women using drugs, like Ozempic, are heading to jewelers in droves to size down their rings. Van Guilder’s ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

A new study from UCLA Health suggests COVID-19 vaccines may protect patients from severe kidney damage. The study found ...

Receding floodwaters that submerged homes days before left the residents of Mthatha, South Africa, helpless. They watched the bodies of their families and ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

England's National Health Service said Friday it is the first health system in the world to offer a targeted blood cancer ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...